Quality of Life Issues During Adjuvant Endocrine Therapy

Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

When the media report the results from studies reporting the latest breakthrough in adjuvant drug treatments, they are usually described in terms of relative rather than absolute benefits. Many women with early stage breast (EBC) cancer may not realise that they do not necessarily require any further adjuvant treatments and that claims for example of a 50% reduction in risk of recurrence does not relate to an individual woman’s risk. For many who receive systemic therapy the relative benefits may be small and not outweigh the associated costs of side effects. Until basic science can provide us with a better understanding of how to target treatments to those most likely to derive benefit, we need to collect side-effect data systematically and conduct considerably more research into ameliorative interventions to help patients cope with the worst symptoms.

References

  1. 1.
    Fallowfield L. Acceptance of adjuvant therapy and quality of life issues. Breast. 2005;14(6):612–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Goodare H, Dimmer C, Page K. ATAC trial: Reporting interim results is not helpful. BMJ. 2003;326(7402):1329.PubMedCrossRefGoogle Scholar
  3. 3.
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974–86.PubMedGoogle Scholar
  5. 5.
    Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999;55(2):189–99.PubMedCrossRefGoogle Scholar
  6. 6.
    Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, et al. A menopause-specific quality of life questionnaire: Development and psychometric properties. Maturitas. 1996;24(3):161–75.PubMedCrossRefGoogle Scholar
  7. 7.
    Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol. 1996;14(10):2756–68.Google Scholar
  8. 8.
    Early, Breast, Cancer, Trialists', Collaborative, Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998;351:1451–67.CrossRefGoogle Scholar
  9. 9.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2.PubMedCrossRefGoogle Scholar
  10. 10.
    Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22(21):4261–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer. Breast Cancer Res Treat 2006;100(3):273–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–92.PubMedCrossRefGoogle Scholar
  13. 13.
    Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet. 2007;369(9561):559–70.Google Scholar
  14. 14.
    Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24(6):910–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262–71.Google Scholar
  16. 16.
    Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931–40.Google Scholar
  17. 17.
    Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, et al. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer. 2003;39(12):1711–7.Google Scholar
  18. 18.
    de Haes H, Olschewski M, Kaufmann M, Schumacher M, Jonat W, Sauerbrei W. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: The Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol. 2003;21(24):4510–6.Google Scholar
  19. 19.
    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20(24):4628–35.Google Scholar
  20. 20.
    Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369(9574):1711–23.Google Scholar
  21. 21.
    Fallowfield L, McGurk R, Dixon M. Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Eur J Cancer. 2004;40(16):2403–10.Google Scholar
  22. 22.
    Fellowes D, Fallowfield LJ, Saunders CM, Houghton J. Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat. 2001;66(1):73–81.Google Scholar
  23. 23.
    Coombes RC, Bliss J, Hall E, Fallowfield L. Under-reporting of symptoms in patients with early breast cancer who have received tamoxifen treatmentfor 2–3 years. Proc ASCO. 2003;22(13):(abs 48).Google Scholar
  24. 24.
    Savage C. He said/she said: How much common agreement is there on symptoms between common toxicity criteria and quality of life ? Proc ASCO. 2002;21(40):(abs 1540).Google Scholar
  25. 25.
    Stead ML, Brown JM, Fallowfield L, Selby P. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer. 2003;88(5):666–71.Google Scholar
  26. 26.
    Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol. 2001;19(7):1885–92.Google Scholar
  27. 27.
    Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol. 2006;17(2):83–4.Google Scholar
  28. 28.
    Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006;17(2):205–10.Google Scholar
  29. 29.
    Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42(14):2271–6.Google Scholar
  30. 30.
    Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59(1):97–102.Google Scholar
  31. 31.
    Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94(6):828–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Jenkins V, Atkins L, Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur J Cancer. 2007;43(9):1342–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Cella D, Fallowfield L. Recognition and management of treatment related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107(2):167–80.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical SchoolUniversity of SussexEast SussexUK
  2. 2.Brighton and Sussex Medical SchoolUniversity of SussexBrightonUK

Personalised recommendations